SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-23-000027
Filing Date
2023-02-23
Accepted
2023-02-23 17:18:02
Documents
13
Period of Report
2023-02-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20230216.htm   iXBRL 8-K 44555
2 EX-10.1 mastertransactionagreement.htm EX-10.1 85395
  Complete submission text file 0001516551-23-000027.txt   274911

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20230216.xsd EX-101.SCH 1921
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20230216_lab.xml EX-101.LAB 22080
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20230216_pre.xml EX-101.PRE 11526
7 EXTRACTED XBRL INSTANCE DOCUMENT skye-20230216_htm.xml XML 10700
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 23661029
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences